Experimental cancer drug GEN1078 trial halted after just 3 patients
NCT ID NCT06771921
First seen Feb 01, 2026 · Last updated May 22, 2026 · Updated 12 times
Summary
This trial tested a new drug, GEN1078, in people with advanced solid tumors that had stopped responding to standard treatments. The study was stopped early after enrolling only 3 participants. Its main goals were to check for side effects, see how the drug moves through the body, and get an early look at whether it might shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centro Integral Oncologico Clara Campal
Madrid, Spain
-
Clinica Universidad de Navarra
Pamplona, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitary Fundacion Jimenez Diaz
Madrid, Spain
-
NEXT Oncology Madrid
Madrid, Spain
-
Righshospitalet (Copenhagen University Hospital)
Copenhagen, Denmark
Conditions
Explore the condition pages connected to this study.